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ABSTRACT
The translation of basic research into improved therapies for breast
cancer patients requires relevant preclinical models that incorporate
spontaneous metastasis. We have completed a functional and
molecular characterisation of a new isogenic C57BL/6 mouse model
of breast cancer metastasis, comparing and contrasting it with the
established BALB/c 4T1 model. Metastatic EO771.LMB tumours were
derived from poorly metastatic parental EO771 mammary tumours.
Functional differences were evaluated using both in vitro assays and
spontaneous metastasis assays in mice. Results were compared to
non-metastatic 67NR and metastatic 4T1.2 tumours of the 4T1 model.
Protein and transcript levels of markers of human breast cancer
molecular subtypes were measured in the four tumour lines, as well
as p53 (Tp53) tumour-suppressor gene status and responses to
tamoxifen in vivo and in vitro. Array-based expression profiling of
whole tumours identified genes and pathways that were deregulated
in metastatic tumours. EO771.LMB cells metastasised spontaneously
to lung in C57BL/6 mice and displayed increased invasive capacity
compared with parental EO771. By immunohistochemical
assessment, EO771 and EO771.LMB were basal-like, as was the
4T1.2 tumour, whereas 67NR had a luminal phenotype. Primary
tumours from all lines were negative for progesterone receptor, Erb-
b2/Neu and cytokeratin 5/6, but positive for epidermal growth factor
receptor (EGFR). Only 67NR displayed nuclear estrogen receptor
alpha (ERα) positivity. EO771 and EO771.LMB expressed mutant
p53, whereas 67NR and 4T1.2 were p53-null. Integrated molecular
analysis of both the EO771/EO771.LMB and 67NR/4T1.2 pairs
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indicated that upregulation of matrix metalloproteinase-3 (MMP-3),
parathyroid hormone-like hormone (Pthlh) and S100 calcium binding
protein A8 (S100a8) and downregulation of the thrombospondin
receptor (Cd36) might be causally involved in metastatic dissemination
of breast cancer.
KEY WORDS: Breast cancer, Syngeneic preclinical models,
Metastasis, Tumour subtyping, Estrogen receptor alpha
INTRODUCTION
The high mortality rate associated with advanced breast cancer is
due primarily to the growth of metastases, mainly targeting liver,
lung, bone and brain. Treating metastatic disease poses many
challenges owing to a lack of knowledge of the critical molecular
targets for therapy and to the acquisition of resistance both to
standard chemotherapy and targeted therapies such as selective
estrogen receptor modulators (SERMs) and the anti-HER2 (human
epidermal growth factor receptor 2; also known as Erb-b2) antibody,
trastuzumab (Eckhardt et al., 2012). The genetic diversity between
different tumours and the inherent heterogeneity of individual breast
lesions poses additional challenges (Russnes et al., 2011; Stephens
et al., 2012).
Gene expression profiling of breast tumours has led to the
identification of up to ten subtypes in humans (Curtis et al., 2012;
The Cancer Genome Atlas Network, 2012; Lehmann et al., 2011;
Perou et al., 2000; Sørlie et al., 2001) and many subtypes in
transgenic mouse models of breast cancer (Herschkowitz et al.,
2007; Pfefferle et al., 2013). These include the well-accepted
luminal A, luminal B, basal-like and HER2-enriched subtypes
(Herschkowitz et al., 2007; Perou et al., 2000; Sørlie et al., 2001).
Immunohistochemical phenotyping of tumours has identified the
minimum set of biomarkers required to distinguish these groups; in
particular, basal-like and triple-negative (ER-, PR- and HER2-
negative) tumours (Blows et al., 2010; Cheang et al., 2008; Nielsen
et al., 2004). However, more relevant prognostic biomarkers and
therapeutic targets are now required within each of the molecular
subtypes of human breast cancer, but especially for basal-like and
triple-negative tumours, for which no targeted therapies currently
exist.
Mouse models of breast cancer include those in which xenografts,
either from human cell lines or directly from patients, are
transplanted into immunocompromised hosts (DeRose et al., 2011).
However, it is becoming increasingly evident that faithful tumour-
stromal interactions are very important for clinically relevant tumour
progression and metastasis. Although xenografts are of value for the
assessment of intrinsic events within the tumour cells, they lack the
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orthologous extracellular matrix (ECM), the species-matched
stromal-tumour interactions and a functional immune system.
Syngeneic mouse models of breast cancer, either transgenic or
transplantable, overcome these limitations. Transgenic mouse
mammary tumour models are of great value to preclinical studies
because they incorporate the initiation of the primary tumour.
However, with some exceptions, including the murine mammary
tumour virus (MMTV)-polyoma middle T antigen (PyMT) (Guy et
al., 1992a) and the MMTVneuNT transgenic mice (Guy et al.,
1992b; Moody et al., 2002; Muller et al., 1988), the timeframe for
tumour development is often months, and metastasis is generally
limited to a modest number of lung nodules (Varticovski et al.,
2007).
For transplantable models, the tumour cells can be inoculated into
the mammary gland as an allograft with genetic and immunological
compatibility and the resulting tumours often progress extensively
beyond localised growth within a timeframe of weeks rather than
months (Varticovski et al., 2007). Genetic manipulation of the cells
prior to tumour establishment is also easily achievable. Thus, for
studies relating to spontaneous metastasis, transplantable models
offer a valuable and cost-efficient alternative. These models are
generally established from tumour cells isolated from spontaneous
mammary tumours in mice (Aslakson and Miller, 1992; Casey et al.,
1951; Lelekakis et al., 1999; Rockwell and Kallman, 1973). The
BALB/c isogenic series of mammary tumour lines collectively
known as ‘the 4T1 model’ has been the principal transplantable
mouse model used to study both tumour- and host-derived factors
involved in spontaneous metastasis (Aslakson and Miller, 1992;
Eckhardt et al., 2005; Kusuma et al., 2012).
Studies of host-derived factors in oncogenesis are facilitated by
inoculating cells into mice that are deficient for the gene under
study. Because the majority of genetically ‘pure’ knockout mice
have been generated on, or backcrossed onto, the C57BL/6
background, it is desirable to have metastatic transplantation models
in this strain. However, C57BL/6 mice are more resistant than
BALB/c mice to mammary tumorigenesis induced by p53 loss
(Kuperwasser et al., 2000) and are more resistant to metastasis
(Hunter, 2012; Lifsted et al., 1998). Moreover, the role of specific
host factors in tumour progression can vary depending on the mouse
strain used (Martin et al., 2008).
We have now developed and characterised a new syngeneic
mouse model of metastatic breast cancer in C57BL/6 mice.
EO771.LMB cells were isolated from a rare metastatic lung nodule
that had disseminated from an orthotopic primary tumour of the
original EO771 mammary adenocarcinoma cell line, derived from a
spontaneous mammary tumour in a female C57BL/6 mouse (Casey
et al., 1951). Herein, we have characterised the in vitro and in vivo
phenotypes of the EO771 and EO771.LMB lines. In addition,
immunohistochemical profiles of EO771 and EO771.LMB tumours
were obtained and compared to those of non-metastatic (67NR) and
highly metastatic (4T1.2) tumours from the 4T1 BALB/c model.
Array-based gene expression profiling was conducted to identify
genes commonly dysregulated in metastatic tumours from both
isogenic pairs.
Based on immunohistochemical analyses using a five-marker
panel and array-based gene expression profiling, we show that these
four tumours display features of both luminal and basal-like
subtypes. Expression profiling of the isogenic non-
metastatic/metastatic pairs identified the genes encoding matrix
metalloproteinase-3 (MMP-3), S100 calcium binding protein A8
(S100a8), S100a9 and parathyroid hormone-like hormone (Pthlh) as
possible drivers of metastatic progression.
RESULTS
In vitro and in vivo characterisation of EO771.LMB: a new syngeneic
model of metastatic breast cancer
EO771.LMB was isolated from a rare spontaneous lung metastasis
from an EO771 tumour-bearing mouse as described in the Materials
and Methods. Both EO771 and EO771.LMB formed
undifferentiated high-grade primary tumours in C57BL/6 mice in
vivo (supplementary material Fig. S1), as did 67NR and 4T1.2 from
the established 4T1 BALB/c model. Following summation of scores
for the number of tubules present, nuclear pleomorphism and the
number of mitoses, each of the four tumour types were considered
high-grade overall. Interestingly, 67NR tumours produced moderate-
grade nuclei, rather than the high-grade nuclei observed in the other
three tumour types (supplementary material Fig. S1).
Analysis of EO771 and EO771.LMB mammary tumours revealed
similar primary tumour growth rates (Fig. 1A) and, when EO771
and EO771.LMB primary tumours were resected 13 days following
implantation, comparable primary tumour weights were recorded
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TRANSLATIONAL IMPACT 
Clinical issue 
Metastatic disease is the most common cause of major morbidity and
death in cancer patients. Approximately 20% of individuals with breast
cancer ultimately die from the disease, nearly all owing to the onset of
incurable metastatic disease. Hence, research efforts should focus on
the identification of metastasis-regulating genes and on the development
of new therapies that could prevent the expansion of secondary
metastatic lesions. An essential component of development and testing
of new pharmacological agents is the assessment of their efficacy in
preclinical settings prior to clinical trials. However, very few preclinical
models that incorporate the relevant features of human metastatic
disease are available. To be relevant to human metastatic breast cancer,
these preclinical models should incorporate tumours that are derived
from syngeneic (genetically identical) animals – so that they can retain
an intact immune system – and tumours should be implanted
orthotopically (in the area in which the cancer typically arises). Because
breast cancer comprises different tumour subtypes, each requiring
different clinical management, it is necessary to develop a range of
preclinical models that can reflect this heterogeneity.
Results
In this work, the authors describe a new mouse model of metastatic
breast cancer based on a spontaneous mammary tumour that arose in
a C57BL/6 mouse. From this line, designated EO771, they have derived
a tumour variant that is metastatic to the lung (called EO771.LMB). The
functional characteristics of EO771 and EO771.LMB tumour lines were
compared to those of a pre-existing and widely used mouse model of
metastatic mammary cancer, using immunohistochemistry and molecular
analyses. By immunohistochemistry, EO771 and EO771.LMB lines were
classified as a basal-like tumour, a subtype with poor prognosis in
humans. Integrated molecular analysis of these tumours revealed
important genes – including those that encode matrix metalloproteinase-
3 (MMP-3) and parathyroid hormone-like hormone (Pthlh) – whose
dysregulation might be causally involved in metastatic dissemination of
breast cancer.
Implications and future directions
This new EO771 metastasis model will provide a valuable option for
assessing genes that regulate metastasis and for developing new
therapies that might be beneficial for individuals with poor-outcome
basal-like tumours, who have a higher probability of developing
metastatic disease. A further advantage of this model is that it grows in
the C57BL/6 mouse strain, which is commonly used to generate
transgenic and knockout mice. Hence, tumours derived from this new
model will be valuable for analysing the contribution of specific host-
derived genes to the metastatic process.
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Fig. 1. Functional characterisation of the parental EO771 tumour line and its metastatic variant, EO771.LMB. (A) Parental EO771 (n=10) and metastatic
variant EO771.LMB (n=5) primary tumour volumes were measured three times per week following implantation of cells into the mammary gland of C57BL/6
mice [mean tumour volume (mm3) ± s.d.]. (B) Primary tumour weights following resection on day 13 after implantation (mean weight ± s.d.; n=8, EO771; n=9,
EO771.LMB). (C) Tumour burden in the lungs (mean ± s.d.) measured by qPCR quantification of mCherry DNA in genomic DNA isolated from whole lungs 2
weeks following primary tumour resection (n=8, EO771; n=9, EO771.LMB). (D,E) Superimposed brightfield/fluorescent image of lungs from EO771 (D) or
EO771.LMB (E) tumour-bearing mice. Arrows indicate tumour nodules. (F,G) Hematoxylin- and eosin-stained lung sections from an EO771- (F) or
EO771.LMB- (G) bearing mouse. Magnification: 40×. T: metastatic tumour deposit. (H) Proliferation of EO771 and EO771.LMB cells (mean ± s.d. of 12
replicate wells of one of three representative experiments). (I) Adhesion of EO771 and EO771.LMB cells to different substrates after 30 min. Adhesion is
represented as the percentage of total cell input [mean of triplicate wells ± s.d. of a representative experiment (n=3) is shown]. (J) Chemotactic migration
towards serum-free medium (SFM) or 5% (v/v) FBS after 5 hours and haptotactic migration towards laminin-511 or vitronectin after 4 hours, using Transwell
inserts. The number of migrated cells was counted from three fields of view per membrane at 20x magnification (mean ± s.d. of one of three independent
experiments). (K) Chemotactic and haptotactic invasion through Matrigel towards 5% (v/v) FBS or laminin-511 using Transwell inserts. The assay was run for
18 hours in triplicate wells and the number of invaded cells counted from three fields of view per membrane at 20x magnification. The data represent the mean
number of invaded cells ± s.d. of one of two independent experiments. (L) Gelatin zymography of triplicate EO771 and EO771.LMB (LMB) conditioned medium
from cells cultured on plastic (upper panel). The positions of molecular weight (MW) markers are shown on the left. The locations of proMMP-9 and MMP-2 are
indicated on the right. Mean proMMP-9 band intensity was sixfold higher for EO771.LMB compared with EO771 (P=0.0003). Conditioned medium from primary
culture of whole bone explant (bone), 67NR and 4T1.2 cells were used as positive controls for active MMP-9 (act-MMP-9) to distinguish from proMMP-9
produced by EO771 lines (lower panel). (M) qRT-PCR analysis of MMP-9 mRNA levels in mouse mammary tumour cell lines cultured on plastic or laminin-511
(LN-511, 2 μg/ml). Triplicate cultures were set up for each condition and triplicate PCR reactions run for each culture. Thus, each data point represents the
mean ± s.d. from nine PCR reactions. Mean expression in EO771 on plastic was set to one. Statistical significance in B,C,I,J,K and M was determined using
the Student’s t-test, whereas that in A and H were determined using two-way ANOVA. *P<0.05; **P<0.01; n/s, not significant. D
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(Fig. 1B). Lung metastatic burden was assessed 2 weeks after
primary tumour resection using various methods. By quantitative
PCR of a reporter gene present only in the tumour cells,
EO771.LMB tumour-bearing mice were shown to have increased
spontaneous lung metastasis (Fig. 1C). Visible surface nodules were
increased in EO771.LMB tumour-bearing mice, but this difference
did not reach statistical significance (supplementary material
Fig. S2). Fluorescence imaging of the mCherry-positive nodules
(Fig. 1D,E) and histological analysis (Fig. 1F,G) revealed the
presence of large metastatic nodules in mice with EO771.LMB
tumours. Metastasis to bone was not detected (data not shown). It is
important to note that counting only visible nodules will miss the
inclusion of micrometastases or those within the lung parenchyma.
However, the trend towards more visible, and hence larger, nodules
on the lungs of EO771LMB-bearing mice might be due to earlier
release of tumour cells from the primary tumour, resulting in earlier
homing of tumour cells to lung and larger metastatic nodules. No
difference in lung colonising ability was found between EO771 and
EO771.LMB cells in experimental metastasis assays following
intravenous inoculation of cells, with both lines giving rise to
extensive lung metastasis (supplementary material Fig. S3),
indicating key differences between the two lines in the early steps
of metastasis.
Using a suite of in vitro surrogate assays for metastasis,
EO771.LMB cells were compared to parental EO771 cells. There
was no morphological distinction between EO771 and EO771.LMB
cell lines cultured in vitro (supplementary material Fig. S4), with
both lines displaying an undifferentiated spindle-shaped
morphology. However, the EO771 and EO771.LMB cells were
larger and had a more elongated shape compared with the 4T1.2
cells. As found in vivo, EO771 and EO771.LMB cells proliferated
at the same rate when cultured in vitro (Fig. 1H). Thus, enhanced
proliferation does not account for the increased metastatic capacity
of EO771.LMB tumours. Similarly, no significant differences were
found between the two lines in their ability to grow independent of
anchorage in soft agar (supplementary material Fig. S5), nor in their
capacity to form mammospheres (supplementary material Fig. S6).
The number and size of the mammospheres formed by day 10 as
primary cultures or by day 7 as secondary mammosphere cultures
was similar between the two lines (supplementary material Fig. S6).
Thus, we cannot conclude that there are any differences in potential
numbers of metastasis-initiating cells between the two lines.
Interaction with the surrounding stroma is an important factor in
metastatic dissemination (Bhowmick et al., 2004; Pouliot et al.,
2013; Zetter, 1993). Hence, the ability to adhere to various ECM
proteins that are present in the microenvironment was measured
(Prince et al., 2002). Both lines showed strongest adhesion to
laminin-511, whereas EO771.LMB cells had a slightly reduced
ability to adhere to vitronectin (Fig. 1I). Neither EO771 nor
EO771.LMB were motile towards fetal bovine serum (FBS) in
chemotactic migration assays but demonstrated robust motility in
haptotactic migration assays towards laminin-511 and to a lesser
extent towards vitronectin (Fig. 1J). However, there were no
differences between the two lines on either substrate. Although both
lines were poorly invasive toward FBS (Fig. 1K), EO771.LMB
showed markedly increased haptotactic invasion through Matrigel
toward laminin-511 compared with EO771 (Fig. 1K). As a
comparison, metastatic 4T1.2 cells were slightly more adherent than
67NR cells on most substrates, with both lines remaining only
weakly adherent to collagen I, collagen IV and fibronectin.
However, 4T1.2 adhesion to vitronectin and laminin-511 was
elevated approximately fourfold compared with 67NR
(supplementary material Fig. S7), consistent with previous results
using Matrigel as the substrate (Eckhardt et al., 2005). We have
shown previously that 4T1-derived metastatic variants display
higher chemotactic migration and invasion than 67NR cells
(Eckhardt et al., 2005), and are particularly migratory and invasive
towards laminin-511 (Chia et al., 2007; Kusuma et al., 2012). These
responses are dependent in part on gelatinase activity (Denoyer et
al., 2014; Sloan et al., 2006). Gelatin zymography assays revealed
the presence of both MMP-2 and MMP-9 in the culture supernatants
of EO771 and EO771.LMB (Fig. 1L, upper panel), with
EO771.LMB showing sixfold higher MMP-9 protein levels
compared with EO771 cells. Only pro-MMP-9 was detected in
EO771 or EO771LMB cells in vitro (Fig. 1L, lower panel). The
absence of detectable active MMP-9 in EO771 and EO771LMB
monocultures is likely to be due to the relatively low abundance of
MMP-9 in these cultures compared to the levels in whole bone
cultures (a positive control for active MMP-9) and/or to the need for
a higher concentration of MMP-3 or other proteases present in vivo
to fully process MMP-9. As reported previously (Tester et al., 2000),
4T1.2 cells produce more active MMP-9 than do 67NR cells
(Fig. 1L, lower panel). Because laminin-511 selectively induced the
invasive capacity of EO771.LMB (Fig. 1K), we evaluated whether
engagement with this substrate modulated MMP-9 expression. Basal
MMP-9 mRNA levels in cells cultured on plastic were 4.5-fold
higher in EO771.LMB compared with EO771 (Fig. 1M), consistent
with the higher protein levels. Culturing of cells on laminin-511
significantly increased MMP-9 mRNA levels by 3.1-fold in EO771
and by 2.4-fold in EO771.LMB relative to the cells seeded on
plastic.
Immunohistochemical profiling of mouse models of breast cancer
Standard clinical phenotyping of human tumours involves
immunohistochemical staining for estrogen receptor alpha (ERα),
progesterone receptor (PR) and HER2 amplification or high
expression, to inform selection of therapy. Additional staining for
cytokeratin 5/6 (KRT5/6), epidermal growth factor receptor (EGFR)
and Ki-67 has also been used as a surrogate for gene expression
profiling to allocate tumours to luminal A, luminal B, HER2 or
basal-like molecular subtypes (Blows et al., 2010). Inclusion of the
three additional markers better predicts survival (Cheang et al.,
2008) and loco-regional relapse (Voduc et al., 2010).
Thus, primary EO771 and EO771.LMB tumours were analysed
by immunohistochemistry (Fig. 2) for markers of the luminal A/B
subtypes (ERα, ERβ, PR), the HER2 subtype (Erb-b2/Neu) and the
basal-like subtype (KRT5/6, EGFR) and compared to 67NR and
4T1.2 tumours. ERα is located in the nuclei of primary human breast
cancers (Pertschuk et al., 1985) and ERα-positive MCF7 xenografts,
but is absent in the triple-negative MDA-MB-231 tumours
(supplementary material Fig. S8). 67NR tumours revealed nuclear
ERα positivity as well as diffuse cytoplasmic staining. Nuclear
staining was negligible in the other three tumours, which instead
showed diffuse cytoplasmic positivity (Fig. 2). Cytoplasmic ERα is
also present at low incidence in human breast cancer specimens
(Welsh et al., 2012), but the significance of this localisation is not
known. The closely related ERβ protein, which is required for
normal terminal differentiation of the murine mammary gland
(Förster et al., 2002), was not present in any of the tumours (Fig. 2).
Similarly, all four tumours were negative for PR and Erb-b2/Neu
protein. In humans, tumours are considered basal-like if they are
negative for nuclear ERα, PR and HER2 (triple-negative) but
positive for KRT5/6 or EGFR (Carey et al., 2006; Cheang et al.,
2008; Nielsen et al., 2004). All four tumours were negative for
RESEARCH ARTICLE Disease Models & Mechanisms (2015) doi:10.1242/dmm.017830
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KRT5/6 protein but positive for EGFR staining (Fig. 2). Therefore,
immunohistochemical analysis indicates that 4T1.2, EO771 and
EO771.LMB have a triple-negative and basal-like phenotype,
whereas 67NR, owing to the presence of nuclear ERα, displays a
mixed luminal/basal phenotype.
p53 status of mouse mammary tumours
Mutations in p53 are associated with the basal-like subtype of breast
cancer (Carey et al., 2006). Because point mutations in p53 stabilise
the protein, a positive signal by immunohistochemistry is commonly
used as a surrogate marker of tumours bearing a missense mutation
(Wynford-Thomas, 1992; Yemelyanova et al., 2011). Both EO771
and EO771.LMB primary tumours showed uniform nuclear staining
for p53, whereas 67NR and 4T1.2 were negative (Fig. 3A).
Constitutive p53 expression by cultured EO771 and EO771.LMB
cells was confirmed by western blot, and protein levels could not be
further enhanced by exposure to ultraviolet (UV) radiation,
indicating the presence of mutant p53. In contrast, p53 is inducible
in mouse embryonic fibroblasts that express wild-type p53
(Fig. 3B). Both control and UV-radiation-exposed 67NR and 4T1.2
cells were negative for p53, which is in agreement with earlier
reports on the 4T1 model (Wang et al., 1998; Yerlikaya and Erin,
2008).
Responses of murine mammary tumours to tamoxifen
Given the lack of nuclear ERα protein but the presence of diffuse
cytoplasmic ERα in the EO771-derived tumours and in 4T1.2
tumours, we determined whether their growth was impacted by
administration of the ERα antagonist tamoxifen to the mice, with
continuous treatment beginning on the day of tumour-cell
inoculation. Tamoxifen significantly inhibited growth of 67NR
tumours (Fig. 4A), consistent with the presence of nuclear ERα.
Tamoxifen administration had no significant effect on the growth of
4T1.2 (Fig. 4B) or EO771.LMB (Fig. 4D), but did reduce growth of
EO771 tumours (Fig. 4C). To help gain insight into epithelial versus
possible stromal actions of tamoxifen in vivo, proliferation in vitro
241
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Fig. 2. Immunohistochemical staining of primary murine mammary tumours for markers of human breast cancer subtypes. From top to bottom:
Luminal marker ERα. A normal mammary duct adjacent to a 67NR tumour was used as a positive control. Arrows indicate examples of ERα-positive nuclei in
67NR tumour and mammary duct. Luminal marker ERβ. A normal mammary duct was used as a positive control with arrows indicating examples of ERβ-
positive nuclei. Luminal marker PR. A normal mammary gland shows high levels of this protein. Erb-b2/Neu. A metastatic tumour from the lungs of an MMTV-
Neu transgenic mouse was used as a positive control. Basal markers cytokeratin 5/6 (Krt5/6) and EGFR. Positive controls (myoepithelial layer of mammary
gland for Krt5/6 and mouse lung for EGFR) are shown at the right of each row. Scale bars: 50 μm.
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was measured in response to the active metabolite 4-
hydroxytamoxifen. 4-hydroxytamoxifen significantly abrogated
proliferation in 67NR cells (Fig. 4E), but had no effect on the
growth rates of 4T1.2, EO771 or EO771.LMB cells (Fig. 4F-H).
Thus, response to tamoxifen in vitro was correlated with the
presence of nuclear ERα; the reduction of EO771 tumour growth
and the trend towards decreased growth of EO771.LMB and 4T1.2
tumours in vivo upon tamoxifen administration might be attributable
to effects on stromal cells.
The different responses to tamoxifen prompted us to assess ERα
transcript levels in tumours and cultured cells (Fig. 5). ERα mRNA
levels in whole 67NR and 4T1.2 tumours were higher than those in
EO771 and EO771.LMB tumours, although no significant
differences were found between 67NR and 4T1.2, or between
EO771 and EO771.LMB pairs (Fig. 5A). However, tumour cells
isolated from 67NR primary tumours expressed three- to four-fold
higher ERα mRNA levels than those from 4T1.2 (Fig. 5B),
confirming their intrinsic responsiveness to tamoxifen. Cells isolated
from EO771.LMB tumours expressed more ERα than did EO771
(Fig. 5B), but the low expression in both lines compared with that
in 67NR indicates that the in vivo responsiveness of EO771 tumours
to tamoxifen is most likely mediated by the stromal compartment.
The differential expression of ERα between 67NR and 4T1.2 and
between EO771 and EO771.LMB was retained when the cells were
cultured in vitro (Fig. 5C).
Gene expression signatures in mouse mammary tumours
To delineate molecular features of the four tumour models
(EO771/EO771.LMB and 67NR/4T1.2), whole primary tumours
were subjected to array-based gene expression profiling and gene
set enrichment analysis (GSEA), completed by applying eight
different gene expression signatures relevant to breast cancer
biology (supplementary material Tables S1-S3; Fig. S9A-H).
According to this genomic analysis, a basal cell expression signature
was not enriched in any of the tumours (supplementary material
Fig. S9A; Table S1); however, a luminal expression signature was
unexpectedly enriched in 4T1.2 tumours (supplementary material
Fig. S9B). EO771 and EO771.LMB tumours both displayed
enrichment of proliferation genes (supplementary material
Fig. S9C), hypoxia-regulated genes (supplementary material
Fig. S9D) and upregulation of a subset of interferon-regulated genes
(supplementary material Fig. S9E), thus distinguishing them from
tumours of the 4T1 model. None of the tumours was significantly
enriched for invasion, epithelial-to-mesenchymal transition (EMT)
or breast cancer stem cell signatures (supplementary material
Fig. S9F-H), indicating that these latter three phenotypes are not the
sole determinants of metastatic capacity.
Gene expression profiling identifies an association of MMP-3, Pthlh
and S100a8 with the metastatic phenotype
To identify candidate genes that might be causal in metastatic
dissemination, the array data were analysed for transcripts
commonly upregulated or downregulated in both 67NR/4T1.2 and
EO771/EO771.LMB isogenic pairs (supplementary material
Fig. S10; Tables S2, S3). Candidate genes common to both pairs
were selected for further interrogation based on fold change, P-value
and extent of differential expression in the EO771/EO771.LMB pair.
Differential gene expression was confirmed by qRT-PCR in whole
tumours (Table 1; supplementary material Fig. S11).
Matrix metalloproteinase-3 (MMP-3) and parathyroid hormone-
like hormone (Pthlh) genes encode secreted factors implicated
previously in breast cancer progression (Kremer et al., 2011;
Sternlicht et al., 1999). These two genes were upregulated in 4T1.2
and EO771.LMB primary tumours compared with their non-
metastatic counterparts, by both microarray and qRT-PCR. The
secreted neutrophil chemotactic factor calprotectin is a stable
heterodimer of the related S100A8 and S100A9 proteins, although
each protein is also able to form homodimers (Ehrchen et al., 2009).
Both proteins are co-expressed in human breast cancers, where they
are associated with aggressive tumour characteristics (Acharyya et
al., 2012; Arai et al., 2008; Moon et al., 2008). Secretion of S100a8
by primary tumours has also been implicated in the formation of the
pre-metastatic niche in mouse lung (Hiratsuka et al., 2008). S100a8
was elevated in both 67NR/4T1.2 and EO771/EO771.LMB tumour
comparisons, although differential expression of S100a9 was found
only in 4T1.2/67NR (Table 1; supplementary material Fig. S11).
Two genes downregulated in metastatic tumours were also
evaluated. Cd36 is a scavenger receptor for oxidized low-density
lipoprotein (LDL) found on the surface of myeloid cells,
erythrocytes, endothelium and adipocytes in the tumour
microenvironment (Koch et al., 2011). It binds collagen and
thrombospondin (Koch et al., 2011), and its loss in tumour stroma
is associated with poor outcome in breast cancer (Defilippis et al.,
2012). Cd36 was downregulated approximately twofold in whole
metastatic tumours from each model (Table 1; supplementary
material Fig. S11). Glycosylation-dependent cell adhesion molecule-
1 (GlyCAM1) is a secreted proteoglycan found in high endothelial
venules of lymph nodes and in murine mammary epithelium during
pregnancy and lactation (Hou et al., 2000). GLYCAM1 expression
has not been evaluated in human breast cancer (Lister et al., 1998).
GlyCAM1 mRNA levels were strongly reduced in the more
metastatic variants of both isogenic pairs but did not reach
significance in 67NR/4T1.2 (Table 1; supplementary material
Fig. S11). Interestingly, GlyCAM1 is induced by prolactin in murine
mammary epithelium (Hou et al., 2000). Accordingly, prolactin
receptor (Prlr) expression was also significantly reduced in
EO771.LMB compared with EO771 (Table 1), indicating that
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Fig. 3. Evaluation of p53 status. (A) Immunostaining of primary tumours for
tumour suppressor p53. Scale bars: 50μm. (B) Cell lines were exposed to
UVC irradiation (+) or sham-irradiated (–) and then assessed 4 hours later for
p53 levels by western blot. The blots were re-probed with an antibody for α-
tubulin as a loading control. UVC-treated mouse embryonic fibroblasts (MEF)
with wild-type p53 were used as a positive control. The data are
representative of two independent experiments.
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attenuated Prlr signalling might be responsible for the lower
GlyCAM1 levels found in EO771.LMB.
Because differential gene expression was shown in whole
tumours, it was unclear whether these genes were expressed by the
tumour cells, by the surrounding stroma, or by both. To check this,
we evaluated expression levels of selected genes in adenocarcinoma
cells isolated directly from the primary tumours by flow cytometry.
MMP-3, S100a8, S100a9 and Pthlh transcripts were all upregulated
significantly in isolated primary tumour cells of the metastatic
variants in both pairs (Fig. 6), reflecting the deregulation observed
in whole tumours. However, Cd36 levels were not significantly
downregulated in the more metastatic tumour cells (Fig. 6). Thus,
the reduction found in whole tumour Cd36 expression is likely to be
due to deregulation in the stroma, as suggested previously
(DeFilippis et al., 2012).
To determine whether differential gene expression in tumour
epithelium requires the unique surroundings of the tumour
microenvironment, transcript levels were also measured in cultured
cells. As observed for primary tumour cells, upregulation of MMP-
3 and S100a8 was also found in the in vitro comparisons of both
67NR/4T1.2 and EO771/EO771.LMB (supplementary material
Fig. S12), indicating that expression of these genes in tumours is
regulated in a cell autonomous way and that tumour epithelium
might be the major site of expression in vivo. However, the
upregulation of Pthlh and S100a9, and the downregulation of Cd36,
observed in primary tumour epithelium were not found consistently
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Fig. 4. Response of primary murine mammary
tumours and cell lines to treatment with an
estrogen receptor antagonist. Mice were implanted
with 67NR (A), 4T1.2 (B), EO771 (C) or EO771.LMB
(D) cells and divided into two groups. One group
received tamoxifen (Tam, 10 μg/g of chow) beginning
on the day of cell implantation and the other did not
receive tamoxifen. For 67NR and 4T1.2 tumour-
bearing mice, n=6/group, for EO771 and EO771.LMB,
n=10/group. Graphs depict the mean tumour volume
(mm3) ± s.d. for each group. (E-H) Response of
cultured tumour cells to treatment with 
4-hydroxytamoxifen (4HT). Cells were incubated with
vehicle alone (1% ethanol) or 4HT at 500 nM.
Proliferation (mean ± s.d. of six replicate wells) was
measured over 4 days. One of two representative
experiments is shown. ***P<0.001 by Student’s t-test.
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in cultured tumour cells from both of the isogenic non-
metastatic/metastatic pairs (supplementary material Fig. S12).
Genes upregulated in the metastatic murine tumours were
evaluated for association with patient outcome in a collection of
human breast cancer datasets (Madden et al., 2013). Higher levels
of MMP-9, S100A8 and S100A9 transcripts were each significantly
associated with worse relapse-free survival over a 20-year interval
when all breast cancers were considered (supplementary material
Fig. S13). However, none of these genes reached statistical
significance when only basal breast cancers were analysed. On the
other hand, although MMP-3 was not prognostic when all breast
cancers were considered, it was prognostic of poor outcome in
basal-like breast cancers (supplementary material Fig. S13).
Expression of PTHLH was not associated with patient survival (data
not shown).
DISCUSSION
A range of mouse models of breast cancer that incorporate
appropriate stromal elements, immune surveillance and spontaneous
metastasis from the mammary gland to distant organs are required
for preclinical testing of novel therapeutics that prevent and/or target
secondary tumours. Here, we report the establishment of a new
syngeneic model of breast cancer metastasis, EO771.LMB in
immunocompetent C57BL/6 mice, a background that is inherently
resistant to metastasis. Functional assays indicated that the
underlying reason for the increased metastatic proclivity of
EO771.LMB compared with EO771 was the acquisition of
enhanced matrix-dependent invasive ability. EO771.LMB expressed
higher levels of MMP-9 and MMP-3 that have been shown to
facilitate tumour cell invasion (Bernhard et al., 1994; Huang et al.,
2009).
We compared the functional and molecular characteristics of
EO771 with those of the well-established 4T1 model. Only 67NR
displayed nuclear ERα and an inhibitory response to tamoxifen both
in vitro and in vivo. Despite the lack of nuclear ERα, EO771 primary
tumours, but not cells in culture, also responded to tamoxifen. We
therefore conclude that tamoxifen might be acting through
modulation of ERα activity in the tumour microenvironment in these
tumours, as reported previously (Gupta et al., 2007; Pontiggia et al.,
2012; Ribas et al., 2011). In luminal human breast cancer, ERα is
usually co-expressed with PR (Stierer et al., 1993), and HER2
expression is usually absent. However, all four mouse tumours were
negative for both PR and Erb-b2/Neu protein. Therefore, the
immunohistochemical data indicate that EO771, EO771.LMB and
4T1.2 are of the core basal phenotype, defined as triple-negative
tumours expressing either CK5/6 and/or EGFR (Blows et al., 2010).
The 67NR tumour is classified as luminal 1 (similar to luminal A),
as defined by Blows et al. (Blows et al., 2010). On the other hand,
our genomic analysis demonstrated that only 18% of the human
luminal gene signature was significantly upregulated in 67NR
tumours, thereby providing discordance between the
immunohistochemical classification and the genomic classification.
Furthermore, none of the three tumours classified as core basal by
immunohistochemistry showed enrichment of basal-like gene
expression by GSEA. Despite harbouring a likely point mutation in
p53, which is associated with a basal-like phenotype in human
tumours, the basal-like genes were no more enriched in EO771 and
EO771.LMB than in 67NR or 4T1.2. Therefore, taken together, the
data show that EO771, EO771.LMB and 4T1.2 are predominantly
basal-like, and that 67NR is predominantly luminal-like. An
additional point of distinction is that 67NR primary tumours have a
moderate level of nuclear pleomorphism, whereas each of the other
three tumour types contained high-grade nuclei.
Several studies of human breast cancer also report discordance
between immunohistochemical and transcriptional profiles. For
example, Gazinska et al. reported that, of 142 triple-negative breast
cancers, 116 basal-like cancers were identified by one of three
classifiers (histology, immunohistochemistry or PAM50 gene
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Fig. 5. Analysis of ERα mRNA expression. (A) qRT-PCR analysis of ERα
mRNA levels in whole primary tumours. Three different primary tumours were
analysed in duplicate by qRT-PCR for each tumour model. Thus, each data
point represents the mean ± s.d. of six qPCR reactions across three different
tumours. Expression in whole mammary gland (MG) was set to 1. (B) qRT-
PCR analysis of ERα mRNA levels in whole mammary gland (MG), cultured
NMuMG cells and in isolated tumour epithelial cells from the indicated
primary tumours. RNA was isolated from the primary tumour cells of two mice
for each tumour type and pooled. Each data point represents the mean ± s.d.
of triplicate reactions. Expression in mammary gland (MG) was set to 1.
(C) qRT-PCR analysis of ERα mRNA levels in cultured mammary tumour cell
lines. Each data point represents the mean ± s.d. of triplicate reactions.
Expression in NMuMG cells was set to 1. AT3 and MH248 murine mammary
tumour lines were used as negative and positive controls, respectively.
*P<0.05; ***P<0.001; n/s, not significant.
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signature), but only 13 cancers were classified as basal-like by all
three methods (Gazinska et al., 2013). Hence, depending on the
classification method used, the subtyping of breast cancers can vary.
Discordance between ERα expression and assessment of molecular
subtype by RNA-based methods has also been observed in human
breast tumours, with between 1 and 3% of ERα-positive tumours
displaying a basal-like phenotype (Perou et al., 2000; Sørlie et al.,
2001; Sorlie et al., 2003). Similarly, up to 60% of tumours classified
as HER2-positive by immunohistochemistry were classified
otherwise by gene expression profiling (de Ronde et al., 2010).
Recent studies have indicated that human basal-like tumours can
contain at least three different subgroups, including ‘claudin-low’,
‘molecular apocrine’ and ‘interferon-rich’. Owing to an upregulation
of interferon-inducible genes, including Ifit1, Ifit3 and Bst2, the
EO771 and EO771.LMB tumours might correspond more closely to
the interferon-rich subtype of human basal-like tumours (Hu et al.,
2006; Teschendorff et al., 2007). The results of these analyses are
broadly in agreement with previous studies of transgenic mouse
models of breast cancer that found conservation of some but not all
features of the principal human breast cancer molecular subtypes
(Herschkowitz et al., 2007; Pfefferle et al., 2013). In summary, the
molecular subtyping of breast cancers based on their transcriptome
varies with the intrinsic gene list or with the single sample predictors
used for the classification (Weigelt et al., 2010). For current clinical
use, histological features of tumours combined with
immunohistochemical assessment of ERα, PR and HER2 are still
the main classifiers used to decide on treatment options.
Integrated genomic analysis of microarray data from primary
tumours of the two different isogenic pairs revealed that MMP-3,
Pthlh and S100a8 were commonly upregulated and that Cd36 was
commonly downregulated, indicating that these genes might be
causal in tumour cell dissemination. All four genes were expressed
by the tumour cells and are also likely to be expressed by several
stromal cell lineages in the tumour microenvironment. Elevated
expression of MMP-3, Pthlh and S100a8 was confirmed in isolated
primary tumour epithelial cells of the two metastatic variants, as was
expression of S100a9, a binding partner for S100a8. MMP-3 and
S100a8 were also upregulated in the metastatic cells in vitro.
However, it is likely that stromal cells contribute to in vivo
expression as well, especially for S100a8 and S100a9. As well as
contributing to the recruitment of neutrophils and myeloid-derived
suppressor cells (MDSCs) into tumours (Ehrchen et al., 2009), the
S100A8-S100A9 heterodimer (calprotectin) is synthesized by
MDSCs and regulates their functions (Acharyya et al., 2012;
Lukanidin and Sleeman, 2012). MDSC-derived calprotectin
enhances survival of human MDA-MB-231 breast cancer xenografts
in a paracrine manner at metastatic sites (Acharyya et al., 2012), and
elevated levels of calprotectin in lung metastases of breast cancer
patients is associated with a worse overall survival (Acharyya et al.,
2012). Both S100a8 homodimers and calprotectin signal via Toll-
like receptor-4 (Tlr4) (Vogl et al., 2007), consistent with expression
of Tlr4 in all four tumour lines (data not shown). Therefore, tumour-
cell-derived S100a8/a9 proteins are likely to signal in both autocrine
and paracrine ways in these tumours.
Pthlh was upregulated in the metastatic tumours from both
models. PTHLH encodes a 36-amino-acid mature peptide strongly
implicated in multiple aspects of breast cancer progression.
However, its roles are complex and yet to be completely elucidated.
A germline polymorphism near PTHLH was associated with
increased risk for the development of both sporadic (Ghoussaini et
al., 2012) and BRCA1-mutation-associated breast cancer (Antoniou
et al., 2012), and tumour expression of PTHLH promotes the
formation of osteolytic lesions in bone (Guise et al., 1996; Sloan and
Anderson, 2002). However, whereas Pthlh activity promoted
primary tumour growth and metastatic dissemination in the MMTV-
PyMT transgenic mouse model of breast cancer (Li et al., 2011), it
delayed tumour initiation in the MMTV-Neu model (Fleming et al.,
2009). PTHLH expression in primary human tumours was also
reported to be associated with ERα positivity and reduced incidence
of bone metastasis (Henderson et al., 2006), as well as improved
overall survival (Henderson et al., 2006; Surowiak et al., 2003).
However, other reports have indicated that primary-tumour PTHLH-
positivity is associated with poorer disease-free survival (Linforth et
al., 2002; Yoshida et al., 2000), an effect that is enhanced if co-
expressed with the PTHLH receptor (Linforth et al., 2002). The
function of PTHLH as either a promoter or attenuator of cancer
progression might depend on the nature of the processed PTHLH
peptides present in the tumour milieu. Interestingly, a recent report
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Table 1. Differential gene expression in two mouse models of breast cancer metastasis
Array qRT-PCR
Transcript Ratio Ratio Ratio Ratio 
Gene Name ID 4T1.2:67NR P-value LMB:EO771 P-value 4T1.2:67NR P-value LMB:EO771 P-value
MMP-3 Matrix metalloproteinase 3 10583071 12.18 <0.005 2.13 0.005 15.47 <0.005 2.37 <0.005
Pthlh Parathyroid hormone-like 10549388 2.28 0.002 2.05 0.052 40.45 <0.005 3.22 0.006
hormone
S100a8 S100 calcium binding 10493831 4.08 0.006 1.83 0.013 8.21 <0.005 2.43 <0.005
protein A8
S100a9 S100 calcium binding 10499861 3.61 <0.005 1.13 0.630 7.42 <0.005 1.12 0.950
protein A9
GlyCAM1 Glycosylation-dependent cell 10433172 0.16 0.112 0.09 0.035 0.16 0.348 0.14 0.050
adhesion molecule-1
Prlr Prolactin receptor 10423049 0.89 0.713 0.32 0.024 nd – nd –
Prlr Prolactin receptor 10423030 0.76 0.219 0.38 0.021 nd – nd –
Cd36 Cd36 antigen (thrombospondin 10528207 0.42 0.022 0.35 0.036 0.48 <0.005 0.42 0.050
receptor)
Gene expression ratios in 4T1.2:67NR and EO771.LMB (LMB):EO771 whole tumour comparisons are shown as determined from Affymetrix Mouse Gene
1.0ST microarrays (three different tumours for each tumour type), and by qRT-PCR (duplicate PCR reactions from each of three different tumours for each
tumour type). P-values were calculated by one-way ANOVA using Partek Genomics Suite v6.6 (for microarray data), or by Student’s t-test (for qRT-PCR data).
Graphical representation of the qRT-PCR results is shown in supplementary material Fig. S11. nd, not done. Prlr and its target GlyCAM1 make up a pathway
downregulated in EO771.LMB compared with EO771.
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showed that MMP-3, known to have broad substrate specificity
(Coussens and Werb, 1996), is capable of processing pro-PTHLH
into its mature form as well as further cleaving mature PTHLH into
smaller bioactive fragments (Frieling et al., 2012). EO771.LMB
cells produce higher MMP-9 levels than do EO771, and we have
shown previously that 4T1.2 cells have higher levels of MMP-9 than
do 67NR (Tester et al., 2000). MMP-3 is also able to process pro-
MMP-9 into its enzymatically active form (Ramos-DeSimone et al.,
1999). Thus, MMP-3 might promote spontaneous metastasis in
4T1.2 and EO771.LMB tumours in part via proteolytic processing
of PTHLH and MMP-9. Indeed, exposure of mammary epithelial
cells to MMP-3 results in the induction of epithelial-to-
mesenchymal transition (Lochter et al., 1997a; Lochter et al., 1997b;
Radisky et al., 2005; Sternlicht et al., 1999), invasion (Lochter et al.,
1997a; Lochter et al., 1997b; Sternlicht et al., 1999), genomic
instability (Radisky et al., 2005) and transformation (Lochter et al.,
1997a; Sternlicht et al., 1999).
In summary, the EO771-derived isogenic model of spontaneous
breast cancer metastasis described here and the 4T1 model described
primarily in previous publications (Eckhardt et al., 2005; Lelekakis
et al., 1999) have enabled the identification of genes and molecular
pathways that might regulate metastasis in two different strains of
mice. These tumour models display features of both luminal and
basal-like cancers, demonstrating their phenotypic diversity as is
seen also in human breast cancer. Because no single model
accurately depicts human breast cancer, a diversity of syngeneic
preclinical models is required for a more comprehensive analysis of
metastasis-regulating genes and for testing new therapies that target
metastatic disease. We have provided a characterisation of the
EO771 metastasis model in C57BL/6 mice that can be used in
addition to other models to improve our ability to understand
metastasis and develop therapies for individuals with advanced
breast cancer.
MATERIALS AND METHODS
Cell lines and cell culture
The EO771 cell line was derived from a spontaneous mammary tumour in
a C57BL/6 mouse (Casey et al., 1951) and was stored in liquid nitrogen
vapour phase. Early-passage parental EO771 cells were transduced with the
pMSCV (murine stem cell virus) retroviral vector expressing the mCherry
fluorescent protein (Denoyer et al., 2011). The lungs from a mouse
orthotopically implanted with EO771_mCherry cells in our laboratory were
excised and sorted by flow cytometry for mCherry-positive cells that were
expanded in culture. This sequence of orthotopic growth in vivo followed
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Fig. 6. qRT-PCR analysis of MMP-3, S100a8, S100a9, Pthlh and
Cd36 mRNA levels in isolated primary tumour cells. RNA was
isolated from the primary tumour epithelium of two mice for each
tumour type and pooled. Each data point represents the mean ± s.d.
of triplicate reactions. For the pairwise comparisons, gene expression
levels in non-metastatic 67NR and EO771 were set to 1 for each
gene analysed. (A) 67NR and 4T1.2. (B) EO771 and EO771.LMB.
*P<0.05; **P<0.01; n/s, not significant.
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by recovery of mCherry-positive cells from the lung was repeated. Upon the
second round of mammary fat-pad injections of these mCherry-positive
cells, visible lung nodules were detected. One of these nodules was
designated Lung Metastasis nodule B and, after being returned to culture,
became the EO771.LMB cell line. 67NR and 4T1 cell lines were derived
from a subpopulation of a single mammary tumour that arose in a
BALB/c/C3H mouse (Aslakson and Miller, 1992), with the 4T1.2 cell line
being derived from a single-cell clone of the 4T1 population (Lelekakis et
al., 1999). EMT6.5 (Ellis et al., 2000) is a single-cell clone derived from the
EMT6 mammary tumour (Rockwell and Kallman, 1973). NMuMG
immortal murine mammary epithelial cells were obtained from ATCC. The
Pik3ca-mutant murine mammary tumour line MH248 was a kind gift from
Dr Wayne Phillips (Tikoo et al., 2012). The murine mammary tumour line
AT3, derived from polyoma-middle T antigen transgenic mice (Stewart and
Abrams, 2007), was a kind gift from Dr Trina Stewart (Griffith University,
Queensland, Australia). 67NR and 4T1.2 mammary adenocarcinoma cells
were maintained in Eagle’s minimum essential medium (alpha modification)
supplemented with 5% (v/v) fetal bovine serum (FBS) (SAFC Biosciences,
Brooklyn, Victoria, Australia) and 1% (v/v) penicillin-streptomycin, whereas
EO771, EO771.LMB, EMT6.5, AT3, MH248 and NMuMG cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing
HEPES (20 mM) supplemented with 10% (v/v) FBS, penicillin (100 IU/ml)
and streptomycin (100 μg/ml). All cells were cultured at 37°C in 5% CO2
(v/v) in air and were maintained in culture for a maximum of 4-5 weeks.
Adhesion assay
Short-term adhesion assays (30 minutes) were completed using the calcein-
AM (Life Technologies, Mulgrave, Victoria, Australia) labelling method as
described previously (Chia et al., 2007). The experiment was repeated three
times with results showing the mean of triplicate wells ± standard deviation
(s.d.) of a representative experiment.
Proliferation assay
Proliferation assays were completed using the sulforhodamine B (SRB)
colorimetric assay as described previously (Vichai and Kirtikara, 2006).
Cells were seeded into 96-well plates at an initial density of 1×103 cells/well.
Proliferation was also assessed in the presence of 500 nM 4-
hydroxytamoxifen (4-HT) dissolved in ethanol and diluted to a final ethanol
concentration of 1% (v/v).
Migration and invasion assays
Migration and invasion assays were run in triplicate porous (8-μm pore size)
Transwell migration chambers (BD Biosciences, Bedford, MA, USA) as
described previously (Chia et al., 2007; Kusuma et al., 2012; Sloan et al.,
2006). Transwells were coated with ECM proteins overnight at 4°C (Chia
et al., 2007). Recombinant human laminin-511 (alpha5beta1gamma1) was
isolated as previously described (Doi et al., 2002), and vitronectin was
obtained from Sigma. For migration assays, cells (2×105/200 μl) in serum-
free medium (SFM) were seeded into the top chamber of the Transwell. For
invasion assays, a cell suspension of 1×105 cells in 50 μl of SFM was mixed
with 50 μl Matrigel (BD Biosciences). 80 μl of the mixture was placed in
the Transwell and allowed to set for 30 minutes, followed by addition of 100
μl of SFM. Cells were allowed to migrate for 4-5 hours or invade for 18
hours. The data represent the mean number of migrated or invaded cells ±
s.d. of a representative experiment (n=3).
Gelatin zymography
Gelatinase assays were completed as described previously (Kusuma et al.,
2011), with minor modifications. Briefly, the cells (5×105/400 μl SFM) were
incubated for 24 hours at 37°C and secreted proteins in the supernatants
separated by SDS-PAGE on 8% polyacrylamide gels supplemented with 1%
bovine gelatin. Proteolytic digestion occurred over the next 24 hours. Gels
were scanned and clear MMP-2 and MMP-9 signals quantitated by
densitometry using ImageJ software (NIH).
UV irradiation and western blotting
Cultured cells were exposed to 7 J/m2 ultraviolet C (UVC) or mock-exposed
and whole-cell lysates prepared 4 hours later. Lysates were separated by SDS-
PAGE, transferred to a nitrocellulose membrane, and incubated overnight with
anti-p53 antibody (1:500, CM5p, Novocastra, Leica Microsystems, North
Ryde, NSW, Australia). Blots were stripped and re-probed with a mouse
monoclonal anti-α-tubulin antibody (1:10,000, T5168, Sigma). Bands were
visualised using a horseradish peroxidase (HRP)-conjugated secondary
antibody and an enhanced chemiluminescence-based detection system.
Quantitative real-time RT-PCR
A representative sample of primary tumour was lysed in Trizol reagent using
a FastPrep automated bench-top homogeniser (MP Biomedical, Seven Hills,
NSW, Australia), and total RNA isolated in accordance with the
manufacturer’s instructions (Life Technologies). Total RNA was
subsequently re-purified using RNeasy mini-columns with on-column
DNaseI digestion (Qiagen, Doncaster, Victoria, Australia). For cell lines,
total RNA was isolated using RNeasy mini-kits with on-column DNaseI
digestion (Qiagen). RNA quality was determined using an RNA6000 Nano
chip and 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
cDNA was synthesised using SuperscriptIII reverse transcriptase (Life
Technologies). qPCR was completed using either inventoried TaqMan gene
expression assays (ERα, ERβ, PR, Erb-b2, Cd36, MMP-3, Glycam1) in a
15 μl reaction volume (Life Technologies) or using SYBR-green reagent
(Life Technologies) in a 15 μl reaction volume in conjunction with the
primers listed in supplementary material Table S4, as previously described
(Johnstone et al., 2004). Rps27a was used as an internal reference gene for
all reactions. PCR reactions were run for 45 cycles in 96-well plates using
a StepOne-Plus real-time PCR platform (Life Technologies).
Primary tumour cell sorting by flow cytometry
The mCherry-expressing 67NR, 4T1.2, EO771 and EO771.LMB primary
tumours were disaggregated by collagenase I digestion (Worthington
Biochemical Corporation, Lakewood, NJ, USA) and filtered through a series
of sieves prior to sorting for mCherry-positive cells using a FACSDiva cell
sorter (BD Biosciences). SYTOX green (Invitrogen) was used to exclude
non-viable cells.
Immunohistochemistry
Tissue sections (6 μm) were stained using a standard protocol. Briefly, slides
were heated for antigen retrieval by pressure cooker treatment in 0.01 M
sodium citrate buffer, pH 6.0 (125°C for 3 minutes, 90°C for 10 seconds).
Sections were blocked in 3% (v/v) normal goat serum in 0.05% (v/v) PBS-
Tween 20 for 1 hour at room temperature. Primary antibody incubation was
conducted in blocking buffer overnight at 4°C. Non-specific rabbit IgG
(Dako, Campbellfield, Victoria, Australia) or mouse IgG (Dako) antibodies
were used as isotype controls. Biotin-conjugated goat anti-rabbit or anti-
mouse secondary antibodies (Dako) were used at 1:250 or 1:300 dilution for
1 hour at room temperature. Specific primary-secondary antibody complexes
were detected using ABC reagent (Vector Laboratories, Burlingame, CA,
USA) and visualised using a 3, 3′-diaminobenzidine peroxidase substrate kit
(Vector Laboratories). Sections were counterstained with hematoxylin,
dehydrated and mounted. The primary antibodies and dilutions used were
as follows: mouse monoclonal anti-human ERα (1:100, clone 1D5, Dako),
chicken polyclonal anti-human ERβ (1:500, a kind gift from Dr Jan-Åke
Gustafsson, University of Houston, TX, USA), rabbit polyclonal anti-human
PR (1:4500, sc-538, Santa Cruz Biotechnology, Dallas, TX, USA), rabbit
polyclonal anti-human HER2 (1:400, A0485, Dako), mouse monoclonal
anti-human cytokeratin 5/6 (KRT5/6, 1:100, clone D5/16 B4, Merck
Millipore, Kilsyth, Victoria, Australia), rabbit polyclonal anti-EGFR (1:50,
ab2430, Abcam, Cambridge, UK) and rabbit polyclonal anti-mouse p53
(1:300, CM5p, Novocastra).
Tumour growth and analysis
Female BALB/c or C57BL/6 mice (obtained from Walter and Eliza Hall
Institute of Medical Research, Parkville, Victoria, Australia) were
maintained in a specific pathogen-free environment and fed ad libitum. All
procedures involving mice conformed to National Health and Medical
Research Council animal ethics guidelines and were approved by the
Animal Experimentation and Ethics Committee (AEEC) of the Peter
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MacCallum Cancer Centre. To generate primary tumours, 1×105 cells were
implanted into the fourth inguinal mammary gland [in 20 μl of Hank’s
balanced salt solution (HBSS)] of 8- to 10-week-old female BALB/c (67NR,
4T1.2 or EMT6.5) or C57BL/6 (EO771 or EO771.LMB) mice. Primary
tumour volume was measured three times per week using electronic
callipers. The greatest longitudinal diameter (length) and the greatest
transverse diameter (width) were measured. Tumour volumes were
estimated by the modified ellipsoidal formula: volume=1/2(length×width2)
(Tomayko and Reynolds, 1989). In resection experiments, primary tumours
were excised at a size of 400-600 mm3. For experiments involving
tamoxifen administration (Xianju Green Leaf Pharmaceutical Factory,
Zhejiang, China), mice were administered tamoxifen (10 μg tamoxifen
citrate per gram of chow), commencing on the day of tumour cell
implantation. Differences in primary tumour growth rates were calculated
by determining the area under each curve using the trapezoid rule (Atkinson,
1989), and then comparing the area under the curve values using a two-
sample Student’s t-test (Bryant, 1983).
Experimental lung metastasis assay
EO771 or EO771.LMB cells (5×105 cells in 200 μl of HBSS) were injected
into C57BL/6 mice via the tail vein using a 26 gauge needle. 19 days later
the metastatic burden in the lung was analysed by TaqMan qPCR.
Analysis of lung metastatic burden
Dissected lungs were stained with India Ink to visualise metastatic nodules
and the number of surface nodules enumerated. Alternatively, metastatic
burden in lung was determined by TaqMan qPCR-based detection of the
mCherry nucleotide sequence in whole lung genomic DNA as described
previously (Denoyer et al., 2011; Eckhardt et al., 2005).
Anchorage independent growth in soft agar
Soft agar assays were conducted in six-well plates as previously described
(Mongroo et al., 2004). Colonies were stained with calceinAM dye (Enzo
Life Sciences, Farmingdale, NY, USA) and fluorescent images generated
(32× magnification) using an Olympus fluorescent dissecting
stereomicroscope. The number of colonies >50 μm in size were counted in
three fields per well and averaged.
Generation of mammospheres
Mammosphere cultures were conducted using serum-free DMEM:Ham’s
F12 medium containing bFGF, EGF and B27 supplement (Life
Technologies) as previously described (Dontu et al., 2003; To et al., 2010).
Briefly, 2000 single and viable cells in 2 ml of medium were seeded in
triplicate into six-well ultra-low-attachment plates (Corning, In Vitro
Technologies, Noble Park North, Victoria, Australia) and primary
mammospheres allowed to form over 10 days. After analysis,
mammospheres were dissociated into single cells using 0.1% (2×) Trypsin-
EDTA at 37°C for 15 min and cell viability determined by Trypan Blue
exclusion. Single cells were again seeded into triplicate wells as above and
secondary mammospheres allowed to form over 7 days. Mammospheres
were imaged using a Leica DM IRB inverted microscope (50×
magnification). Only mammospheres with a diameter of >150 μm were
counted. Mammosphere area was determined using ImageJ software (NIH).
Xenograft tumour growth
One million MCF-7 or MDA-MB-231 human breast cancer cells were
inoculated into the 4th mammary gland of NOD scid gamma (NSG) mice
and allowed to grow for 6 weeks. Mice implanted with MCF-7 cells were
supplemented with 1 μM 17β-estradiol in the drinking water ad libitum.
Tumours were fixed overnight in 10% neutral buffered formalin prior to
processing for immunohistochemistry.
Gene expression profiling
Total RNA was isolated from primary tumours using the procedure
described above. In solution DNaseI digestion (TURBO DNase, Ambion,
Life Technologies) was completed on a portion of the total RNA, followed
by verification of RNA integrity using a RNA6000 Nano chip and 2100
Bioanalyzer (Agilent Technologies). RNA was processed using NuPAGE
reagents (Affymetrix, Santa Clara, CA, USA) and applied to GeneChip
Mouse Gene 1.0ST Arrays as per the manufacturer’s instructions
(Affymetrix). Three different tumours were processed per tumour type (15
tumours in total). A confocal scanner was used to acquire the fluorescence
signal after excitation at 570 nm. Background adjustment, quantile
normalization and median-polish summarization was completed using the
GC Robust Multi-array Average (GCRMA) algorithm. Microarray profiling
data were deposited into the Gene Expression Omnibus (G.E.O.) with
Accession No. GSE42272 (http://www.ncbi.nlm.nih.gov/geo/).
Bioinformatics
Affymetrix .cel files were obtained and differential gene expression between
4T1.2/67NR and EO771.LMB/EO771 calculated by one-way ANOVA using
Partek Genomics Suite v6.6 (Partek Inc., St Louis, MO, USA). Gene set
enrichment analysis was completed using the R program (http://www.R-
project.org/). Firstly, the mean expression level of each gene was calculated
across 15 different tumours (three each from 67NR, 4T1.2, EO771,
EO771.LMB and EMT6.5). Then, the number of genes within each signature
that were significantly upregulated or significantly downregulated (P<0.05) in
67NR, 4T1.2, EO771 or EO771.LMB tumours was calculated relative to the
mean expression level of each gene across all 15 tumours analysed. Gene
expression signatures were obtained from the Molecular Signatures Database
(http://www.broadinstitute.org/gsea/msigdb/index.jsp) or from the following
references: basal epithelial (54 genes) (Huper and Marks, 2007), luminal
epithelial (59 genes) (Huper and Marks, 2007), proliferation (97 genes)
(Ghazoui et al., 2011), hypoxia-regulated (75 genes) (Dowsett et al., 2011),
core EMT markers (91 genes) (Taube et al., 2010), interferon-regulated (27
genes) (Einav et al., 2005), breast cancer stem cells (93 genes) (Creighton et
al., 2009) and cancer cell invasion (64 genes) (Kim et al., 2010).
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